Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026838 (
spasticity
)
6,471
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The neurotransmitter gamma-aminobuteric acid (GABA) is believed to have a controlling action on spinal locomotor networks. In
spasticity
, spinal locomotor networks are thought to play a role. A well known drug in the treatment of
spasticity
is the GABA(B) agonist Baclofen. We report an inhibitory effect of Baclofen on the
ANP
-mediated cGMP synthesis in the superficial dorsal horn (laminae I-III) of the rat cervical spinal cord. This inhibitory effect of Baclofen could not be detected after incubation with the NO donor SNP. The clinical effect of Baclofen on the reduction of
spasticity
might be explained by an enhancement of GABAergic inhibition of
ANP
mediated cGMP concentration in the spinal cord dorsal horn, thus reducing afferent input.
...
PMID:Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord. 1187 70
